NOVN.VX - Novartis AG

Swiss - Swiss Delayed Price. Currency in CHF
80.66
+2.46 (+3.15%)
At close: 5:30PM CEST
Stock chart is not supported by your current browser
Previous Close78.20
Open80.00
Bid81.00 x 373700
Ask80.50 x 1281100
Day's Range79.56 - 81.06
52 Week Range72.96 - 88.30
Volume6,499,612
Avg. Volume4,463,523
Market Cap205.733B
BetaN/A
PE Ratio (TTM)23.65
EPS (TTM)N/A
Earnings DateJul 18, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est88.59
  • Business + Coffee: Novartis delays price hikes, US govt pays Trump golf course, Papa John fights board
    Yahoo Finance Video5 hours ago

    Business + Coffee: Novartis delays price hikes, US govt pays Trump golf course, Papa John fights board

    Wednesday, July 18: Novartis says it will follow Pfizer in delaying planned price hikes after pressure from Trump; US government paid $77,000 to President Donald Trump’s Turnberry golf resort in Scotland before he stayed there; Papa John Schnatter says he regrets resigning as chairman of Papa John’s and is fighting back against the board. Yahoo Finance’s Dan Roberts serves up the news of the day -- on his birthday!

  • Novartis CEO Says It's `Prudent' to Pull Back From Further Price Increases
    Bloomberg Video12 hours ago

    Novartis CEO Says It's `Prudent' to Pull Back From Further Price Increases

    Jul.18 -- Novartis AG Chief Executive Officer Vas Narasimhan talks about U.S. drug pricing, government health-care policy and plans to spin off the Swiss drugmaker's Alcon eye-care unit. He speaks from Basel, Switzerland, on "Bloomberg Daybreak: Europe" after profit beat estimates in the second quarter, allowing Novartis to reiterate its full-year forecast.

  • Reuters4 hours ago

    Novartis hints at 2018 outlook hike despite drug price freeze

    Novartis (NOVN.S) may ratchet up its 2018 sales outlook, its finance chief said on Wednesday, despite halting planned U.S. drug price hikes amid pressure on the industry from President Donald Trump's administration over the high cost of medicines. Shares in the Swiss drugmaker, whose decision to freeze prices this year in the world's largest drug market was mirrored by Pfizer (PFE.N), closed 2.5 percent higher in Zurich after the firm beat forecasts with second-quarter results.

  • Novartis hints at 2018 outlook hike despite drug price freeze
    Reuters4 hours ago

    Novartis hints at 2018 outlook hike despite drug price freeze

    Novartis (NOVN.S) may ratchet up its 2018 sales outlook, its finance chief said on Wednesday, despite halting planned U.S. drug price hikes amid pressure on the industry from President Donald Trump's administration over the high cost of medicines. Shares in the Swiss drugmaker, whose decision to freeze prices this year in the world's largest drug market was mirrored by Pfizer (PFE.N), closed 2.5 percent higher in Zurich after the firm beat forecasts with second-quarter results.

  • Barrons.com4 hours ago

    Novartis Earnings: 'A Focused Company Wins,' Says CEO

    Shares of Novartis (NVS) are climbing on Wednesday after the company reported second-quarter earnings. For the full year, Novartis reaffirmed guidance, saying it expects revenue percentage growth of low- to mid-single digits. The report comes after a number of changes at Novartis, including plans to spin off the Alcon eye-care business, the purchase of gene-therapy company AveXis, and the divestiture of its stake in a consumer health-care business joint venture with GlaxoSmithKline (GSK).

  • Novartis’s Business Segments in Q2 2018
    Market Realist6 hours ago

    Novartis’s Business Segments in Q2 2018

    As we’ve already seen, Novartis (NVS) surpassed Wall Street analysts’ estimates for Q2 2018 and reported revenues of $13.2 billion. That’s a 7% growth YoY (year-over-year) compared to $12.2 billion in Q2 2017. Novartis AG is the holding company providing healthcare solutions. Its business is classified into the following three business segments: Innovative Medicines: prescription medicines Sandoz: generics Alcon: eye care

  • Novartis AG (NVS) Q2 2018 Earnings Conference Call Transcript
    Motley Fool6 hours ago

    Novartis AG (NVS) Q2 2018 Earnings Conference Call Transcript

    NVS earnings call for the period ending June 30, 2018.

  • The Wall Street Journal6 hours ago

    [$$] Novartis Won't Raise U.S. Drug Prices This Year

    Novartis won’t increase its U.S. drug prices for the rest of 2018, the Switzerland-based drugmaker said, days after Pfizer took a similar step following criticism from President Trump.

  • Novartis Reports Growth in Q2 2018 Earnings
    Market Realist7 hours ago

    Novartis Reports Growth in Q2 2018 Earnings

    Novartis (NVS) released its Q2 2018 earnings on July 18 and surpassed Wall Street analysts’ estimates for revenues and EPS. It reported revenues of $13.2 billion and EPS of $1.29, which compares to the estimated EPS of $1.28 on revenues of $13 billion.

  • Benzinga8 hours ago

    Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on July 17) Avid Bioservices Inc (NASDAQ: CDMO )( reversed to a profit ...

  • Reuters10 hours ago

    Novartis joins Pfizer in halting U.S. drug price hikes

    Novartis expects to hit the top of its 2018 sales guidance after a strong second quarter, the CEO said, despite joining Pfizer in freezing its U.S. drug prices for the rest of the year following pressure from President Donald Trump. Chief Executive Vas Narasimhan said Novartis would likely easily achieve mid-single digit percentage sales growth for 2018, on rising demand for psoriasis-and-arthritis drug Cosentyx and robust sales of heart-failure medicine Entresto. "We would expect to see, assuming continued momentum like we're seeing now, to be at the high end of that range," Narasimhan said, adding that this would come without price hikes as Novartis keeps the lid on medicine costs under pressure from U.S. lawmakers and Trump.

  • Associated Press12 hours ago

    Novartis: 2Q Earnings Snapshot

    The Basel, Switzerland-based company said it had net income of $3.31 per share. Earnings, adjusted for non-recurring gains, came to $1.26 per share. The results fell short of Wall Street expectations. ...

  • Novartis CEO Says It's `Prudent' to Pull Back From Further Price Increases
    Bloomberg12 hours ago

    Novartis CEO Says It's `Prudent' to Pull Back From Further Price Increases

    Novartis AG Chief Executive Officer Vas Narasimhan talks about U.S. drug pricing, government health-care policy and plans to spin off the Swiss drugmaker's Alcon eye-care unit. He speaks from Basel, Switzerland, ...

  • Associated Press14 hours ago

    Swiss drugs giant Novartis says profit up as spinoff looms

    GENEVA (AP) — Novartis says net profit rose 3 percent in the second quarter amid strong growth for some of its top products, as the Swiss pharmaceuticals giant moves to spin off its Alcon eye-care business.